Detection of 13q abnormalities in multiple myeloma using immunomagnetically selected plasma cells

Neoplasma

Volumn 49, Issue 5, 2002, Pages 300-306

  Fiserova A ^a   Hajek R ^a   Holubova V ^a   Buchler T ^a   Sobotka, J ^a   Kovarova L ^a   Musilova R ^a   Bourkova L ^a   Bulikova A ^a   Mareschova I ^a   Janackova Z ^a   Vanova P ^a   Kuglik P ^a   Vorlicek J ^a   Penka, M ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

13q14 deletion; Interphase fluorescence in situ hybridization; Magnetic activated cell separation; Multiple myeloma; Syndecan 1

Indexed keywords

ANTIBODY; SYNDECAN 1;

ANTIBODY SPECIFICITY; ARTICLE; BONE MARROW EXAMINATION; CELL STRUCTURE; CELL SUSPENSION; CELL VIABILITY; CHROMOSOME 13Q; CHROMOSOME DELETION; CHROMOSOME G BAND; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMAGNETIC SEPARATION; INTERPHASE; MITOSIS; MULTIPLE MYELOMA; MYELOMA CELL; PLASMA CELL;

EID: 0036448450     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Anderson KC, Hamblin TJ, Traynor A. Management of multiple myeloma today. Semin Hematol 1999; 36: 3-8.
2. Avet-Loiseau H, Daviet A, Brigaudeau C, Callet-Bauchu E, Terré C, Lafage-Pochitaloff M, Désangles F, Ramond S, Talmant P, Bataille R. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: A study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Francais de Cytogenetique Hématologique. Blood 2001; 97: 822-825.
3. Avet-Loiseau H, Li JY, Morineau N, Facon T, Brigaudeau C, Harousseau JL, Grosbois B, Bataille R. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Blood 1999; 94: 2583-2589.
4. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
5. Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL, Lose E. Biology of the syndecans: A family of transmembrane haparan sulfate proteoglycans. Annu Rev Cell Biol 1992; 8: 365-393.
6. Carlebach M, Amiel A, Gaber E, Radnay J, Manor Y, Fejgin M, Lishner M. Multiple myeloma: Monoallelic deletions of the tumor suppressor genes TP53 and RB1 in long-term follow-up. Cancer Genet Cytogenet 2000; 117: 57-60.
7. Chang H, Bouman D, Boerkoef CF, Stewart AK, Squire JA. Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization. Leukemia 1999; 13: 105-109.
8. Chorváth B, Sedlák J. Hematopoietic cell differentiation (antigens CD system 1997). Cancer research relevance. Neoplasma 1998; 45: 273-276.
9. Cigudosa JC, Rao PH, Calasanz MJ, Odero MD, Michaeli J, Jhanwar SC, Chaganti RSK. Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood 1998; 91: 3007-3010.
10. Couchman J, Woods A. Syndecans, signaling, and cell adhesion. J Cell Biochem 1996; 61: 578-584.
11. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, Zangari M, Munshi NC, Anaissie E, Spoon D, Siegel D, Jagannath S, Vesole D, Epstein J, Shaughnessy J, Fassas A, Lim S, Roberson P, Crowley J. Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008-4010.
12. Dewald GW, Kyle RA, Hicks GA, Greipp PR. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985; 66: 380-390.
13. Drach J, Schuster J, Nowotny H, Angerler J, Rosenthal F, Fiegl M, Rothermundt C, Gsur A, Jäger U, Heinz R, Lachner K, Ludwig H, Huber H. Multiple myeloma: High incidence of chromosopmal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res 1995; 55: 3854-3859.
14. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, Lai JL, Leleu X, Jouet JP, Bauters F, Harousseau JL, Bataille R, Mary JY. Chromosome 13 abnormalities identified by FISH analysis and serum μ2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566-1571.
15. Facon T, Lai JL, Nataf E, Preudhomme C, Zandecki M, Hammmad M, Wattel E, Jouet JP, Bauters F. Improved cytogenetic analysis of bone marrow plasma sells after cytokine stimulation in multiple myeloma: A report on 46 patients. Br J Haematol 1993; 84: 743-745.
16. Gould J, Alexanian R, Goodacre A, Pathak S, Hecht B, Barlogie B. Plasma cell karyotype in multiple myeloma. Blood 1988; 71: 453-456.
17. Hallek M, Bergsagel L, Anderson KC. Multiple myeloma: Increasing evidence for a multistep transformation process. Blood 1998; 91: 3-21.
18. Harada H, Kawano MM, Huang N, Harada Y, Iwato K, Tanabe O, Tanaka H, Sakai A, Asaoku H, Kuramoto A. Phenotypic diference of normal plasma cells from mature myeloma cells. Blood 1993; 81: 2658-2663.
19. Jarošová M, Ščudla V, Indrák K, Kapustová M. Cytogenetic examination in multiple myeloma. I. Chromosomal findings in 56 patients. Vnitr Lek 1990; 36: 1072-1080.
20. Joshua D, Petersen A, Brown R, Pope B, Snowdon L, Gibson J. The labelling index of primitive plasma cells determines the clinical behviour of patients with myelomatosis. Br J Haematol 1996; 94: 76-81.
21. Kawano MM, Huang N, Harada H, Sakai A, Tanaka H, Iwato K, Kuramoto A. Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood 1993; 82: 564-570.
22. Kawano MM, Huang N, Tanaka H, Ishikawa H, Sakai A, Tanabe O, Nobuyoshi M, Kuramoto A. Homotypic cell aggregation of human myeloma cells with ICAM-1 and LFA-1 molecules. Br J Haematol 1991; 79: 583-588.
23. Klabusay M, Doubek M, Adam Z, Hájek R. Monitoring of residual disease of patients with multiple myeloma by flowcytometry. In: Adam Z, Hájek R, Mayer J, Ščudla V, Vorlíček J, editors. Multiple Myeloma and Other Monoclonal Gammopathies. Brno: Masaryk university, 1999: 157-173.
24. Lai JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M, Morel P, Jouet JP, Bauters F, Facon T. Improved cytogenetics in multiple myeloma: A study of 151 patients including 117 patients at diagnosis. Blood 1995; 85: 2490-2497.
25. Mitelman F, editor. ISCN (1995): An International System for Human Cytogenetic Nomenclature. Basel: Karger, 1995.
26. Pérez-Simón JA, García-Sanz R, Tabernero MD, Almeida J, González M, Fernández-Calvo J, Moro MJ, Hernández JM, San Miguel JF, Orfaó A. Prognostic value of numerical cromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. Blood 1998; 91: 3366-3371.
27. Pope B, Brown RD, Gibson J, Petersen A, Wiley J, Joshua DE. The functional phenotype of the primitive plasma cell in patients with multiple myeloma correlates with the clinical state. Leuk Lymphoma 1997; 27: 83-91.
28. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995; 82: 41-49.
29. Shaughnessy J, Barlogie B. Chromosome 13 deletion in myeloma. Curr Top Microbiol Immunol 1999; 246: 199-203.
30. Shaughnessy J, Tian E, Sawyer J, Bumm K, Landes R, Badros A, Morris C, Tricot G, Epstein J, Barlogie B. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 2000; 96: 1505-1511.
31. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, Naucke S, Sawyer JR. Poor prognosis in multiple myeloma is associated only with partial or complete deletion of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood, 86(11), 1995, 4250-4256.
32. Tricot G, Sawyer JR, Jagannath S, Desikan R, Siegel D, Naucke S, Mattox S, Bracy D, Munshi N, Barlogie B. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 1997; 15: 2659-2666.
33. Weh HJ, Fiedler W, Hossfeld DK. Cytogenetics in multiple myeloma: Are we studying the "right" cells? Eur J Haematol 1990; 45: 236-237.
34. Witzig TE, Klimlinger T, Stenson M, Therneau T. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1998; 31: 167-175.
35. Zandecki M, Lai JL, Facon T. Multiple myeloma: Almost all patients are cytogenetically abnormal. Br J Haematol 1996; 94: 217-227.
36. Zojer N, Königsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E, Kaufmann H, Riedl L, Gisslinger H, Schreiber S, Heinz R, Ludwig H, Huber H, Drach J. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000; 95: 1925-1930.